MAPPING ETANERCEPT BIOSIMILARS
Posted in News
Etanercept (Enbrel) biosimilar Benepali has been marketed in the UK since February this year for the treatment of some chronic inflammatory diseases.
As we have seen with the introduction of the Infliximab biosimilars, we would anticipate there being considerable uptake and cost saving.
Your peer group uptake can be seen in Define “Usage > Hospital Indicators > Biosimilars”.
Prior to the release of Benepali, Rx-info mapped all existing records for Etanercept to Enbrel, and now will allocate only the brand described in the drug description. Any ambiguous mappings will report as “Generically mapped.”